Post-Traumatic Stress Disorder (PTSD) Market Research Report - Global Forecast till 2025

Post-Traumatic Stress Disorder (PTSD) Market Forecast

ID: MRFR/HC/6904-HCR | February 2021 | Region: Global | 100 pages

The Global Post-Traumatic Stress Disorder (PTSD) Market is expected to cross USD 7.3 Billion by 2025 at a CAGR of 4.8%.


Market Synopsis


Post-Traumatic Stress Disorder (PTSD) occurs by experiencing life-threatening events such as natural disasters, serious accidents, military combat, terrorist incidents, or sexual assault in adult or childhood. Most survivors of trauma return to normal given a little time. However, some people will have stress reactions that do not go away on their own or may even get worse over time. These individuals might develop PTSD.  People who have PTSD often remember their experience through flashbacks or nightmares. They may have difficulty sleeping and may feel detached as these symptoms can be severe enough and might last long enough to impair the person’s daily life significantly.


Market Influencer


Increasing research regarding the use of cannabidiol (CBD) for the treatment of Post-Traumatic Stress Disorder (PTSD).


Market Drivers



  • Rising prevalence of PTSD

  • Increasing cases of cross-border tensions and violence- PTSD is most commonly associated with soldiers returning from war and has attracted widespread attention in the United States for its effects on veterans of the Iraq and Afghanistan wars. Thus, the increasing number of violence has increased the incidences of PTSD.

  • Rising sexual assault cases- The rate of homicides in Brazil is one of the highest in the World.

  • The rising number of emerging therapies for PTSD treatment

  • An increasing number of clinical trials

  • Increasing rehabilitation programs for injured military personnel

  • Rising incidences of road accidents

  • Launch of a new medication to manage the symptoms of post-traumatic stress disorder

  • A growing number of initiatives by public and private organizations


Market Restraints



  • Side effects due to some specific drugs


Post-Traumatic Stress Disorder (PTSD) Market Segmentation

By Treatment



  • Psychotherapy: In January 2017, nearly 46.6 million adults are affected by the mental disorder in the US. Behavioral therapies, such as cognitive-behavioral therapy (CBT), help to manage stress and deal with potential triggers as well as aid in enhancing self-esteem and altering negative thoughts. It is estimated that 32% to 53% of patients attend cognitive behavioral therapy every year.

  • Medication: It is projected to be the largest segment. Currently, paroxetine (Paxil) and sertraline (Zoloft) are the only medications that have been approved by the US Food and Drug Administration (FDA) for the treatment of PTSD.


By End-User



  • Hospitals and Clinics: The largest segment, hospitals, and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals who have PTSD. Growing awareness and increasing efficiency of hospital staff is projected to drive the growth of this segment during the forecast period.

  • Ambulatory Surgical Centers: A small segment, these centers provide immediate pain relief and rudimentary surgical care.

  • Others: This segment includes home care and senior citizen centers.


By Region



  • Americas: It is the largest region in the PTSD treatment market. Around 7.8% of Americans experiences PTSD at some point in their lives, with women (10.4%) twice as likely as men (5%) to develop PTSD. Approximately 5.2 million people of the US adults aged 18 to 54 have PTSD in 2017. 60.7% of men and 51.2% of women in the US have reported to experience at least one traumatic event. The traumatic events most often associated with PTSD are rape, childhood neglect, physical attack, combat exposure, sexual molestation, and childhood physical abuse.



  • Europe: Sexual violence is a severe public health and human rights problem with both short- and long-term consequences on women's health. In 2015, around 215,000 violent sexual crimes were recorded in the European region, of which 80,000 were rapes. Also, increasing (research & development) R&D in the therapeutics field and the presence of pharmaceutical giants along is providing a spur to the growth of the region.



  • Asia-Pacific: It is the fastest-growing region due to increasing rate of motor accidents. In India, 147,649 road accident cases were reported in 2015.



  • Middle East & Africa: The region is anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.


Key Players



  • GlaxoSmithKline (UK)

  • Pfizer (US)

  • Eli Lilly and Company (US)

  • Lundbeck A/S (Denmark)

  • Azevan Pharmaceuticals (US)

  • Marinus Pharmaceuticals, Inc. (US)

  • Tonix Pharmaceuticals Holding Corp. (US)

  • Bionomics (Australia)

  • Greenstone LLC (US)

  • Mylan NV (US)



Frequently Asked Questions (FAQ) :


The post-traumatic stress disorder market valuation would be USD 7.3 billion by 2025.

The CAGR for post-traumatic stress disorder market would be 4.8% during the forecast period.

The hospitals & clinics segment has the largest post-traumatic stress disorder market segment.

The Americas would dominate post-traumatic stress disorder market.

The Asia Pacific post-traumatic stress disorder market would be the fastest-growing regional market.

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment

6.1 Introduction

6.2 Psychotherapy

6.2.1 Cognitive therapy

6.2.2 Exposure therapy

6.2.3 Eye movement desensitization and reprocessing (EMDR)

6.3 Medication

6.3.1 Antidepressants

6.3.1.1 Paroxetine

6.3.1.2 Sertraline

6.3.1.3 Mirtazapine

6.3.1.4 Amitriptyline or phenelzine

6.3.2 Anti-anxiety medications

6.3.2.1 Beta-blockers

6.3.2.2 Benzodiazepines

6.3.3 Prazosin

Chapter 7. Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User

7.1 Introduction

7.2 Hospitals and Clinics

7.3 Ambulatory Surgical Centers

7.4 Others

Chapter 8. Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 US

8.2.1.2 Canada

8.2.2 Latin America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 UK

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-Pacific

8.5 Middle East & Africa

Chapter 9. Competitive Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Developments & Strategies

9.3.1 Key Developments

Chapter 10 Company Profiles

10.1 GlaxoSmithKline

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Products Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2 Pfizer

10.2.1 Company Overview

10.2.2 Financial Overview

10.2.3 Products Offered

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.2.6 Key Strategies

10.3 Eli Lilly and Company

10.3.1 Company Overview

10.3.2 Financial Overview

10.3.3 Products Offered

10.3.4 Key Developments

10.3.5 SWOT Analysis

10.3.6 Key Strategies

10.4 H. Lundbeck A/S

10.4.1 Company Overview

10.4.2 Financial Overview

10.4.3 Products Offered

10.4.4 Key Developments

10.4.5 SWOT Analysis

10.4.5 Key Strategies

10.5 Azevan Pharmaceuticals

10.5.1 Company Overview

10.5.2 Financial Overview

10.5.3 Products Offered

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.5.6 Key Strategies

10.6 Marinus Pharmaceuticals, Inc.

10.6.1 Company Overview

10.6.2 Financial Overview

10.6.3 Products Offered

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.6.6 Key Strategies

10.7 Tonix Pharmaceuticals Holding Corp.

10.7.1 Company Overview

10.7.2 Financial Overview

10.7.3 Products Offered

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.7.6 Key Strategies

10.8 Bionomics

10.8.1 Company Overview

10.8.2 Financial Overview

10.8.3 Products Offered

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.8.6 Key Strategies

10.9 Greenstone LLC

10.9.1 Company Overview

10.9.2 Financial Overview

10.9.3 Products Offered

10.9.4 Key Developments

10.9.5 SWOT Analysis

10.9.6 Key Strategies

10.10 Mylan NV

10.10.1 Company Overview

10.10.2 Financial Overview

10.10.3 Products Offered

10.10.4 Key Developments

10.10.5 SWOT Analysis

10.10.6 Key Strategies

10.11 Others

Chapter 11. Appendix

11.1. References

11.2. Related Reports

LIST OF TABLES

Table 1 Global Post-Traumatic Stress Disorder (PTSD) Treatment Synopsis, 2019–2025

Table 2 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Estimates & Forecast, 2019–2025, (USD Million)

Table 3 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region, 2019–2025 (USD Million)

Table 4 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2019–2025 (USD Million)

Table 5 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2019–2025 (USD Million)

Table 6 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2019–2025 (USD Million)

Table 7 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2019–2025 (USD Million)

Table 8 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region, 2019–2025 (USD Million)

Table 9 North America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2019–2025 (USD Million)

Table 10 North America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2019–2025 (USD Million)

Table 11 Latin America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2019–2025 (USD Million)

Table 12 Latin America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2019–2025 (USD Million)

Table 13 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2019–2025 (USD Million)

Table 14 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2019–2025 (USD Million)

Table 15 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region, 2019–2025 (USD Million)

Table 16 Western Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2019–2025 (USD Million)

Table 17 Western Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2019–2025 (USD Million)

Table 18 Eastern Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2019–2025 (USD Million)

Table 19 Eastern Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2019–2025 (USD Million)

Table 20 Asia-Pacific: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2019–2025 (USD Million)

Table 21 Asia-Pacific: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2019–2025 (USD Million)

Table 22 Middle East & Africa: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2019–2025 (USD Million)

Table 23 Middle East & Africa: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2019–2025 (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation of the Global Post-Traumatic Stress Disorder (PTSD) Treatment Market

Figure 3 Market Dynamics for the Global Post-Traumatic Stress Disorder (PTSD) Treatment Market

Figure 4 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Treatment, 2018

Figure 5 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by End User, 2018

Figure 6 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Region, 2018

Figure 7 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Region, 2018

Figure 8 North America: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2018

Figure 9 Latin America: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2018

Figure 10 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2018

Figure 11 Asia-Pacific: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2018

Figure 12 Middle East & Africa: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2018

Figure 13 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market: Company Share Analysis, 2018 (%)

Figure 14 GlaxoSmithKline: Key Financials

Figure 15 GlaxoSmithKline: Segmental Revenue

Figure 16 GlaxoSmithKline: Regional Revenue

Figure 17 Pfizer: Key Financials

Figure 18 Pfizer: Segmental Revenue

Figure 19 Pfizer: Regional Revenue

Figure 20 Eli Lilly and Company: Key Financials

Figure 21 Eli Lilly and Company: Segmental Revenue

Figure 22 Eli Lilly and Company: Regional Revenue

Figure 23 H. Lundbeck A/S: Key Financials

Figure 24 H. Lundbeck A/S: Segmental Revenue

Figure 25 H. Lundbeck A/S: Regional Revenue

Figure 26 Azevan Pharmaceuticals: Key Financials

Figure 27 Azevan Pharmaceuticals: Regional Revenue

Figure 28 Azevan Pharmaceuticals: Key Financials

Figure 29 Marinus Pharmaceuticals, Inc.: Segmental Revenue

Figure 30 Marinus Pharmaceuticals, Inc.: Regional Revenue

Figure 31 Marinus Pharmaceuticals, Inc.: Key Financials

Figure 32 Tonix Pharmaceuticals Holding Corp.: Segmental Revenue

Figure 33 Tonix Pharmaceuticals Holding Corp.: Regional Revenue

Figure 34 Tonix Pharmaceuticals Holding Corp.: Key Financials

Figure 35 Bionomics: Segmental Revenue

Figure 36 Bionomics: Regional Revenue

Figure 37 Bionomics: Key Financials

Figure 38 Greenstone LLC: Segmental Revenue

Figure 39 Greenstone LLC: Regional Revenue

Figure 40 Greenstone LLC: Key Financials

Figure 41 Mylan NV: Segmental Revenue

Figure 42 Mylan NV: Regional Revenue

Figure 43 Mylan NV: Key Financials



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.